How I treat hemochromatosis

Blood

Volumn 116, Issue 3, 2010, Pages 317-325

  Adams, Paul C ^a   Barton, James C ^b,c  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b SOUTHERN IRON DISORDERS CENTER   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFEROXAMINE; PROTON PUMP INHIBITOR; HFE PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; IRON; MEMBRANE PROTEIN; SIDEROPHORE;

BLOOD DONOR; BONE MARROW TOXICITY; CREATININE BLOOD LEVEL; CYTAPHERESIS; DIET THERAPY; FATIGUE; GASTROINTESTINAL SYMPTOM; GROWTH; HEARING DISORDER; HEMOCHROMATOSIS; HOMOZYGOTE; HUMAN; HYPOVOLEMIA; INJECTION SITE REACTION; IRON ABSORPTION; IRON DEFICIENCY; IRON DEPLETION; IRON OVERLOAD; LIVER TOXICITY; MAINTENANCE THERAPY; NEPHROTOXICITY; PATIENT MONITORING; PHLEBOTOMY; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; VISUAL DISORDER; YERSINIA INFECTION; ZINC DEFICIENCY; CHELATION THERAPY; FEMALE; GENETICS; IRON INTAKE; MALE; METABOLISM;

BLOOD DONORS; CHELATION THERAPY; CYTAPHERESIS; DEFEROXAMINE; FEMALE; HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HOMOZYGOTE; HUMANS; IRON; IRON, DIETARY; MALE; MEMBRANE PROTEINS; PHLEBOTOMY; PROTON PUMP INHIBITORS; SIDEROPHORES;

EID: 77955906218     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-01-261875     Document Type: Review

References (99)

1. Adams PC, Barton JC. Haemochromatosis. Lancet. 2007;370(9602):1855-1860.
2. Camaschella C. BMP6 orchestrates iron metabolism. Nat Genet. 2009;41(4):386-389.
3. Crosby WH. A history of phlebotomy therapy for hemochromatosis. Am J Med Sci. 1991;301(1):28-31.
4. Tavill A, Adams PC. A diagnostic approach to hemochromatosis. Can J Gastroenterol. 2006;20(8):535-540.
5. Bacon BR, Britton RS. The pathology of hepatic iron overload: a free radical-mediated process? Hepatology. 1990(1):11:127-137.
6. Crosby WH. Hemochromatosis: treatment to alleviate injury. Arch Intern Med. 1986;146(10):1910-1911.
7. Fleming R, Britton R, Waheed A, Sly W, Bacon BR. Pathophysiology of hereditary hemochromatosis. Semin Liver Disease. 2005;25(4):411-419.
8. Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med. 2005;352(17):1769-1778.
9. Barton J, McDonnell S, Adams PC, et al. Management of hemochromatosis. Ann Intern Med. 1998;129(11):932-939.
10. Pankow JS, Boerwinkle E, Adams PC, et al. HFE C282Y homozygotes have reduced low-density lipoprotein cholesterol: the Atherosclerosis Risk in Communities (ARIC) Study. Transl Res. 2008;152(1):3-10.
11. Olynyk J, Cullen D, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med. 1999;341(10):718-724. (Pubitemid 29407371)
12. Andersen RV, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard BG. Hemochromatosis mutations in the general population: iron overload progression rate. Blood. 2004;103(8):2914-2919. (Pubitemid 38451659)
13. Gurrin LC, Osborne NJ, Constantine CC, et al. The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis. Gastroenterology. 2008;135(6):1945-1952.
14. Yamashita C, Adams PC. Natural history of the C282Y homozygote of the hemochromatosis gene (HFE) with a normal serum ferritin level. Clin Gastroenterol Hepatol. 2003;1(5):388-391. (Pubitemid 37248059)
15. Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med. 2008;358(3):221-230.
16. Adams PC. Natural history of hemochromatosis: heading down the up escalator? Gastroenterology. 2008;135(6):1855-1857.
17. Adams PC. The natural history of untreated HFE-related hemochromatosis. Acta Haematol. 2009;122(2-3):134-139.
18. Barton JC. Ferritin>1000: grand for hemochromatosis screening? Blood. 2008;111(7):3309.
19. McDonnell S, Preston B, Jewell S, et al. A survey of 2,851 patients with hemochromatosis: symptoms and response to treatment. Am J Med. 1999;106(6):619-625.
20. McDonnell S, Grindon A, Preston B, Barton J, Edwards C, Adams PC. A survey of phlebotomy among persons with hemochromatosis. Transfusion. 1999;39(6):651-656.
21. Asberg A, Hveem K, Thorstensen K, et al. Screening for hemochromatosis - high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol. 2001;36(10):1108-1115. (Pubitemid 32801699)
22. Asberg A, Hveem K, Kruger O, Bjerve K. Persons with screening-detected haemochromatosis: as healthy as the general population? Scand J Gastroenterol. 2002;37(6):719-724. (Pubitemid 34620937)
23. Powell LW, Dixon JL, Ramm GA, et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med. 2006;166(3):294-301.
24. Falize L, Guillygomarch A, Perrin M, et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology. 2006;44(2):472-477. (Pubitemid 44214887)
25. Adhoute X, Foucher J, Laharie D, et al. Diagnosis of liver fibrosis using FibroScan and other noninvasive methods in patients with hemochromatosis: a prospective study. Gastroenterol Clin Biol. 2008;32(2):180-187. (Pubitemid 351635694)
26. Shizukuda Y, Bolan CD, Tripodi DJ, et al. Does oxidative stress modulate left ventricular diastolic function in asymptomatic subjects with hereditary hemochromatosis? Echocardiography. 2009;26(10):1153-1158.
27. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 1996;110(4):1107-1119. (Pubitemid 26113751)
28. Schumacher HR Jr. Arthropathy in hemochromatosis. Hosp Pract. 1983;33(3):81-90.
29. Waalen J, Felitti V, Gelbart T, Ho N, Beutler E. Prevalence of hemochromatosis-related symptoms among individuals with mutations in the HFE gene. Mayo Clin Proc. 2002;77(6):522-530. (Pubitemid 34587340)
30. Wojcik J, Speechley M, Kertesz A, Chakrabarti S, Adams P. Natural history of C282Y homozygotes for haemochromatosis. Can J Gastroenterol. 2002;16(5):297-302. (Pubitemid 34846665)
31. Adams PC, Speechley M, Kertesz AE. Long-term survival analysis in hereditary hemochromatosis. Gastroenterology. 1991;101(2):368-372.
32. Osborne NJ, Gurrin LC, Allen KJ, et al. HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology. 2010;51(4):1311- 1318.
33. Beutler E, Felitti V. The C282Y mutation does not shorten life span. Ann Intern Med. 2002;162(10):1196-1197. (Pubitemid 34522414)
34. Dabestani A, Child JS, Henze E, et al. Primary hemochromatosis: anatomic and physiologic characteristics of the cardiac ventricles and their response to phlebotomy. Am J Cardiol. 1984;54(1):153-160.
35. Hershko C, Graham G, Bates GW, Rachmilewitz EA. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol. 1978;40(2):255-263. (Pubitemid 9040657)
36. Brissot P, Loreal O. Role of non-transferrin bound iron in the pathogenesis of iron overload and toxicity. Adv Exp Med Biol. 2002;509:45-53. (Pubitemid 37523737)
37. Hider RC. Nature of nontransferrin-bound iron. Eur J Clin Invest. 2002;32(suppl 1):50-54.
38. Gutteridge JM, Rowley DA, Griffiths E, Halliwell B. Low-molecular-weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis. Clin Sci. 1985;68(4):463-467. (Pubitemid 15127670)
39. Le Lan C, Loreal O, Cohen T, et al. Redox active plasma iron in C282Y/C282Y hemochromatosis. Blood. 2005;105(11):4527-4531. (Pubitemid 40720804)
40. Aruoma OI, Bomford A, Polson RJ, Halliwell B. Nontransferrin-bound iron in plasma from hemochromatosis patients: effect of phlebotomy therapy. Blood. 1988;72(4):1416-1419. (Pubitemid 18265915)
41. Lynch SR, Skikne BS, Cook JD. Food iron absorption in idiopathic hemochromatosis. Blood. 1989;74(6):2187-2193. (Pubitemid 19269129)
42. Adams PC. Factors affecting rate of iron mobilization during venesection therapy for hereditary hemochromatosis. Am J Hematol. 1998;58(1):16-19.
43. Olynyk JK, Luxon BA, Jeffrey GP, Britton R, Bacon BR. Hepatic iron concentration in hereditary hemochromatosis does not saturate or accurately predict phlebotomy requirements. Am J Gastroenterol. 1998;93(3):346-350. (Pubitemid 29068334)
44. Phatak PD, Barton JC. Phlebotomy-mobilized iron as a surrogate for liver iron content in hemochromatosis patients. Hematology. 2003;8(6):429-432.
45. Barton JC, Bottomley SS. Iron deficiency due to excessive therapeutic phlebotomy in hemochromatosis. Am J Hematol. 2000;65(3):223-226.
46. Powell LW, Jazwinska E, Halliday J. Primary iron overload. In: Brock J, Halliday J, Pippard MJ, Powell L, eds. Iron Metabolism in Health and Disease. London, United Kingdom: WB Saunders; 1994:227-270.
47. Jandl JH. The hypochromic anemias and other disorders of iron metabolism. In: Jandl J, ed. Blood: Textbook of Hematology. Boston, MA: Little, Brown; 1987:181-235.
48. Bolan CD, Conry-Cantilena C, Mason G, Rouault TA, Leitman SF. MCV as a guide to phlebotomy therapy for hemochromatosis. Transfusion. 2001;41(6):819-827. (Pubitemid 32538521)
49. Price L, Kowdley K. The role of iron in the pathophysiology and treatment of chronic hepatitis C. Can J Gastroenterol. 2009;23(12):822-828.
50. Wallace D, Subramaniam V. Co-factors in liver disease: the role of HFE-related hereditary hemochromatosis and iron. Biochim Biophys Acta. 2009;1790(7):663-670.
51. Adams PC, Kertesz AE, Valberg LS. Rate of iron reaccumulation following iron depletion in hereditary hemochromatosis. Implications for venesection therapy. J Clin Gastroenterol. 1993;16(3):207-210.
52. Witte DL, Crosby WH, Edwards CQ, Fairbanks VF, Mitros FA. Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis. Clin Chim Acta. 1996;245(2):139-200.
53. Seamark C, Hutchinson M. Controversy in primary care: should asymptomatic haemochromatosis be treated? BMJ. 2000(7245):320:1314-1317. (Pubitemid 30245722)
54. Kellner H, Zoller WG. Repeated isovolemic large-volume erythrocytapheresis in the treatment of idiopathic hemochromatosis. Z Gastroenterol. 1992;30(11):779-783. (Pubitemid 23008795)
55. Mariani R, Pelucchi S, Perseghin P, Corengia C, Piperno A. Erythrocytapheresis plus erythropoietin: an alternative therapy for selected patients with hemochromatosis and severe organ damage. Haematologica. 2005;90(5):717-718. (Pubitemid 40780906)
56. Rombout-Sestrienkova E, van Noord PA, van Deursen CT, Sybesma BJ, Nillesen-Meertens AE, Koek GH. Therapeutic erythrocytapheresis versus phlebotomy in the initial treatment of hereditary hemochromatosis - A pilot study. Transfus Apher Sci. 2007;36(3):261-267. (Pubitemid 47089103)
57. Conte D, Mandelli C, Cesana M, Ferrini R, Marconi M, Bianchi A. Effectiveness of erythrocytapheresis in idiopathic hemochromatosis - report of 14 cases. Int J Artif Organs. 1989;12(1):59-62. (Pubitemid 19036800)
58. Nielsen P, Fischer R, Buggisch P, Janka-Schaub G. Effective treatment of hereditary haemochromatosis with desferrioxamine in selected cases. Br J Haematol. 2003;123(5):952-953. (Pubitemid 37533309)
59. Phatak P, Brissot P, Bonkovsky H, et al. A phase I/II, open-label, dose-escalation trial of once daily oral chelator deferasirox to treat iron overload in HFE-related hereditary hemochromatosis. Blood. 2010;114:Abstract 1514.
60. Fabio G, Minonzio F, Delbini P, Bianchi A, Cappellini MD. Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH). Blood. 2007;109(1):362-364. (Pubitemid 46070125)
61. Barton JC. Chelation therapy of iron overload. Curr Gastroenterol Rep. 2007;9(1):74-82.
62. Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut. 2007;56(9):1291-1295. (Pubitemid 47300432)
63. Gunshin H, Mackenzie B, Berger U, et al. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature. 1997;388(6641):482- 488. (Pubitemid 27328927)
64. Gunshin H, Fujiwara Y, Custodio AO, Direnzo C, Robine S, Andrews NC. Slc11a2 is required for intestinal iron absorption and erythropoiesis but dispensable in placenta and liver. J Clin Invest. 2005;115(5):1258-1266. (Pubitemid 40629044)
65. Aymard JP, Aymard B, Netter P, Bannwarth B, Trechot P, Streiff F. Haematological adverse effects of histamine H2-receptor antagonists. Med Toxicol Adverse Drug Exp. 1988;3(6):430-448. (Pubitemid 19013532)
66. Walan A, Strom M. Metabolic consequences of reduced gastric acidity. Scand J Gastroenterol. 1985;111(suppl):24-30. (Pubitemid 15105120)
67. Allen KJ, Nisselle AE, Collins VR, Williamson R, Delatycki MB. Asymptomatic individuals at genetic risk of haemochromatosis take appropriate steps to prevent disease related to iron overload. Liver Int. 2008;28(3):363-369. (Pubitemid 351279584)
68. McLaren GD, Nathanson MH, Jacobs A, Trevett D, Thomson W. Regulation of intestinal iron absorption and mucosal iron kinetics in hereditary hemochromatosis. J Lab Clin Med. 1991;117(5):390-401.
69. Greenwood D, Cade J, Moreton J, et al. HFE genotype modifies the influence of heme iron intake on iron status. Epidemiology. 2005;16(6):802-805. (Pubitemid 41681548)
70. Cade JE, Moreton JA, O'Hara B, et al. Diet and genetic factors associated with iron status in middle-aged women. Am J Clin Nutr. 2005;82(4):813-820. (Pubitemid 43779695)
71. van der AD, Peeters PH, Grobbee DE, Roest M, Voorbij HA, van der Schouw YT. HFE genotypes and dietary heme iron: no evidence of strong gene-nutrient interaction on serum ferritin concentrations in middle-aged women. Nutr Metab Cardiovasc Dis. 2006;16(1):60-68.
72. Leggett BA, Brown NN, Bryant SJ, Duplock L, Powell LW, Halliday JW. Factors affecting the concentrations of ferritin in serum in a healthy Australian population. Clin Chem. 1990;36(7):1350-1355. (Pubitemid 120012245)
73. Milward EA, Baines SK, Knuiman MW, et al. Non-citrus fruits as novel dietary environmental modifiers of iron stores in people with or without HFE gene mutations. Mayo Clin Proc. 2008;83(5):543-549.
74. Robins-Browne RM, Rabson AR, Koornhof HJ. Generalized infection with Yersinia enterocolitica and the role of iron. Contrib Microbiol Immunol. 1979;5:277.
75. Bezwoda WR, Bothwell TH, Derman DP, MacPhail AP, Torrance JD, Charlton RW. Effect of diet on the rate of iron accumulation in idiopathic haemochromatosis. S Afr Med J. 1981;59(7):219-222.
76. Layrisse M, Martinez-Torres C, Cook JD, Walker R, Finch CA. Iron fortification of food: its measurement by the extrinsic tag method. Blood. 1973;41(3):333-352.
77. Olsson KS, Safwenberg J, Ritter B. The effect of iron fortification of the diet on clinical iron overload in the general population. Ann N Y Acad Sci. 1988;526:290-300.
78. Bothwell TH, Derman D, Bezwoda WR, Torrance JD, Charlton RW. Can iron fortification of flour cause damage to genetic susceptibles idiopathic haemochromatosis and beta-thalassaemia major)? Hum Genet Suppl. 1978;1:131-137. (Pubitemid 9076790)
79. Olsson K, Vaisanen M, Konar J, Bruce A. The effect of withdrawal of food iron fortification in Sweden as studied with phlebotomy in subjects with genetic hemochromatosis. Eur J Clin Nutr. 1997;51(11):782-786. (Pubitemid 27485006)
80. Barton JC, Lee PL, West C, Bottomley SS. Iron overload and prolonged ingestion of iron supplements: clinical features and mutation analysis of hemochromatosis-associated genes in four cases. Am J Hematol. 2006;81(10):760-767. (Pubitemid 44536744)
81. Piperno A, Girelli D, Nemeth E, et al. Blunted hepcidin response to oral iron challenge in HFE-related hemochromatosis. Blood. 2007;110(12):4096-4100. (Pubitemid 350248467)
82. Heritage ML, Murphy TL, Bridle KR, Anderson GJ, Crawford DH, Fletcher LM. Hepcidin regulation in wild-type and Hfe knockout mice in response to alcohol consumption: evidence for an alcohol-induced hypoxic response. Alcohol Clin Exp Res. 2009;33(8):1391-1400.
83. Ohtake T, Saito H, Hosoki Y, et al. Hepcidin is down-regulated in alcohol loading. Alcohol Clin Exp Res. 2007;31(1 suppl):S2-S8.
84. Flanagan JM, Peng H, Beutler E. Effects of alcohol consumption on iron metabolism in mice with hemochromatosis mutations. Alcohol Clin Exp Res. 2007;31(1):138-143. (Pubitemid 46025376)
85. Powell LW. The role of alcoholism in hepatic iron storage disease. Ann N Y Acad Sci. 1975;252:124-134.
86. Kaltwasser JP, Werner E, Schalk K, Hansen C, Gottschalk R, Seidl C. Clinical trial on the effect of regular tea drinking on iron accumulation in genetic haemochromatosis. Gut. 1998;43(5):699-704. (Pubitemid 28520107)
87. Barton JC, Acton RT. Hemochromatosis and Vibrio vulnificus wound infections. J Clin Gastroenterol. 2009;43(9):890-893.
88. Edwards CQ, Griffen LM, Goldgar D, Drummond C, Skolnick MH, Kushner JP. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med. 1988;318(21):1355-1362.
89. Levstik M, Adams PC. Eligibility and exclusion of hemochromatosis patients from voluntary blood donation. Can J Gastroenterol. 1998;12(1):61-63. (Pubitemid 28105542)
90. Barton J, Grindon A, Barton N, Bertoli L. Hemochromatosis probands as blood donors. Transfusion. 1999;39(6):578-585.
91. Leitman S, Browning J, Yau Y, et al. Hemochromatosis subjects as allogeneic blood donors: a prospective study. Transfusion. 2003;43(11):1538- 1544. (Pubitemid 37371823)
92. Power T, Adams PC. Hemochromatosis patients as voluntary blood donors. Can J Gastroenterol. 2004;18(6):393-396. (Pubitemid 39076993)
93. Barton J, Sublett S, Boyd G. Management of hemochromatosis in a Jehovah's witness. Am J Hematol. 2005;78(1):83.
94. Sanchez AM, Schreiber GB, Bethel J, et al. Prevalence, donation practices, and risk assessment of blood donors with hemochromatosis. JAMA. 2001;286(12):1475-1481. (Pubitemid 33015504)
95. Newman B. Hemochromatosis blood donor programs: marginal for the red blood cell supply but potentially good for patient care. Transfusion. 2004;44(10):1535-1537.
96. Friedrich C. Blood donation by patients with hemochromatosis [letter; comment]. JAMA. 1993;270(24):2928-2929. (Pubitemid 24000796)
97. Worwood M, Darke C. Serum ferritin, blood donation, iron stores and haemochromatosis. Transfus Med. 1993;3(1):21-28.
98. Courtois F, Danic B. Genetic hemochromatosis and blood donation [in French]. Ann Med Interne (Paris). 2001;152(7):452-454. (Pubitemid 34111906)
99. Blacklock HA, Dewse M, Bollard C, Hudson P, Barnhill D, Jackson S. Blood donation by healthy individuals with haemochromatosis. N Z Med J. 2000;113(1105):77-78.